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Abstract
Background:  Normal coronary arteries may coexist with abnormal coronary and systemic
endothelial function in patients with chest pain. Recent work by the renowned Pisa echo-group
elegantly suggests that isolated ST-segment depression during stress-echo (SE) can be used as a
marker of coronary endothelial dysfunction, in the absence of stress-inducible wall motion
abnormalities and in the absence of angiographically-significant coronary artery disease (CAD). The
long chain n-3 polyunsaturated fatty acids (PUFAs) have been reported to possess several
properties that may positively influence vascular function. The present study's hypothesis is that a
4 month-course of oral supplementation with n-3 PUFAs can reverse endothelial dysfunction.
Methods: Subjects were selected on the basis of the following criteria: 1) reported chest pain
syndrome, 2) significant ST-segment depression during an otherwise normal SE, 3) absence of
angiographically-significant CAD. Subjects underwent a 4-month course of oral supplementation
with commercially available n-3 PUFA, 1 g once a day. Normalization of endothelial dysfunction was
defined, at the end of the supplementation period, by the absence of significant ST-segment
depression during repeat SE. We tested the aforementioned hypothesis in a very small series of
consecutive subjects, with the intent to produce a hypothesis-generating study.
Results: Seven out of the total nine subjects enrolled (77.8%) had normal ST-segment during
repeat SE performed after the 4 month course of therapy.
Conclusions: A striking rate of reversion of SE-induced ST-segment depression after oral n-3
PUFAs suggests reversion of coronary endothelial dysfunction; nonetheless these data need to be
validated in larger, placebo-controlled studies.
Background
Normal coronary arteries may coexist with abnormal cor-
onary and systemic endothelial function in patients with
chest pain [1]. The functional status of systemic endothe-
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lium somewhat mirrors the coronary endothelial function
[2,3] and can be evaluated non-invasively with brachial
ultrasound [4]. A novel, provocative paper by the Pisa
echo-lab group [5,6], suggests that endothelial dysfunc-
tion strictly correlates with ST-segment depression (STSD)
during pharmacologic (as well as exercise) stress, while
epicardial coronary artery stenosis exclusively affects wall
motion abnormalities (WMA), although both compo-
nents may coexist; they demonstrated that abnormal bra-
chial artery flow-mediated dilation (measured with
brachial artery ultrasound) was predicted by STSD during
SE but not by either presence of WMA during SE or angio-
graphically significant CAD. There was no correlation
between brachial artery flow-mediated dilation and extent
of angiographical CAD.
Therefore isolated STSD during SE could be used as a sur-
rogate for coronary endothelial dysfunction, in the
absence of stress-inducible WMA and in the absence of
angiographically-significant CAD.
The majority of cardiovascular benefits of PUFAs are likely
to be mediated in the vascular wall and at the vascular
endothelium level. The long chain PUFAs have been
reported to possess several properties that may positively
influence vascular function. These include favorable
mediator profiles (nitric oxide, eicosanoids) that influ-
ence vascular reactivity, change in vascular tone via
actions on selective ion channels [7], and maintenance of
vascular integrity. In addition to direct effects on contrac-
tility, PUFAs may affect vascular function by modifying
expression of inflammatory cytokines and adhesion mol-
ecules. These properties may explain the beneficial cardi-
ovascular protection of this family of fatty acids that have
been clearly evident through epidemiological data as well
as from few clinical trials [8,9].
Although many epidemiological surveys and basic
research studies have suggested that "marine fish oil" car-
dioprotective effect is consistent and at least partly medi-
ated through an action on the endothelium, no large
clinical intervention trial has yet addressed the effect of
commercially-available PUFAs preparations on a clini-
cally-measurable direct marker of coronary endothelial
dysfunction in normocholesterolemic subjects [10,11]. A
small, randomized study performed in hypercholestero-
lemic subjects suggests a positive effect of 4-month
marine oil supplementation on brachial artery endothe-
lium-mediated vasodilation.[12]
The present study's hypothesis is that a 4 month-course of
oral supplementation with PUFAs can reverse coronary
endothelial dysfunction. Eventual "normalization" of
endothelial dysfunction was measured, at the end of the
supplementation period, by the absence of both signifi-
cant STSD and WMA during repeat SE.
Methods
Patients were enrolled in the study if they met the follow-
ing inclusion criteria: (1) chest pain syndrome; (2) refer-
ence for SE; (3) presence of STSD (strict ECG criteria were
applied: a) STSD ± 1 mm 0.08 s after the J point in the
peripheral leads and/or b) STSD ≥ 2 mm 0.08 s after the J
point in the precordial leads) during a SE with no changes
in wall motion score, (4) coronary angiogram performed
within 20 days after SE, (5) no nitrate therapy at the time
of SE.
When meeting the aforementioned entry criteria, patients
had their total cholesterol measured by means of a stand-
ard whole-blood sample.
Subjects were referred for SE because of one of the follow-
ing: (a) patients with positive exercise-ECG in concomi-
tance with conditions lowering the positive predictive
value of the ECG marker of ischaemia (for instance,
female gender or arterial hypertension); (b) patients with
recurring chest pain in the absence of significant electro-
cardiographic changes during routine exercise-ECG; (c)
patients unable to exercise. All of the patients underwent
dipyridamole SE.
The following were exclusion criteria: (1) uninterpretable
resting ECG (left bundle branch block, preexcitation,
baseline STSD or elevation > 1 mm, or typical digitalis
repolarization pattern); (2) technically poor acoustic win-
dow; (3) cardiomyopathy or severe valvular disease; (4)
previously detected CAD; (5) statin therapy; (6) high total
cholesterol levels (defined as total cholesterol ≥ 240 mg/
dl as suggested by current NCEP guidelines).
The study was approved by the institutional review board.
All patients gave their written informed consent before
entering the study.
Stress echo was performed with dipyridamole up to 0.84
mg/kg over 10 min with atropine up to 2 mg when
needed; stress echo was repeated using the same protocol
after a 4-month course of oral supplementation with com-
mercially available (Seacor®, Esapent®, Eskim®) n-3 PUFA
at a dose of 1 g once a day. An imaging system with digital
acquisition was used (GE-Vivid 7). All standard echocar-
diographic views were obtained when possible. The left
ventricle was divided into 16 segments, as suggested by
the American Society of Echocardiography. Segmental
wall motion was graded as follows: normal = 1; hypoki-
netic = 2; akinetic = 3; and dyskinetic = 4. Inadequately
visualized segments were not scored. Stress echo was con-
sidered positive when one left ventricular segment wasBMC Cardiovascular Disorders 2004, 4 http://www.biomedcentral.com/1471-2261/4/1
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increased by one grade or more at peak stress. Normaliza-
tion of coronary endothelial dysfunction was defined as
isoelectric ST segment 0.08 s after the J point in the
peripheral leads and STSD < 0.5 mm 0.08 s after the J
point in the precordial leads during repeat SE with no
WMA.
Coronary angiography in multiple views was performed
according to the standard Judkins or Sones technique.
The percent diameter stenosis was determined by quanti-
tative coronary angiography. A vessel was considered to
have significant obstruction if its diameter was narrowed
by 50% or more, with respect to the pre-stenotic tract.
Results
Nine consecutive patients were prospectively enrolled
according to inclusion/exclusion criteria during the time
period between January 2003 and June 2003. Three
patients (out of the 12 who fulfilled entry criteria) were
excluded because of the presence of at least one exclusion
criteria (2 subjects had high total cholesterol levels as per
protocol defined and one was already on statin therapy).
Five patients were male (55%); mean age was 60(± 5).
Four patients (44%) had hypertension (treated with ACE-
inhibitors, ARBs, diuretics or combinations of them),
3(33%) had diabetes (treated with a combination of met-
formin and a sulfonylurea), 2(22%) had total cholesterol
levels in the range between 200 mg/dl and 240 mg/dl
(defined as borderline high by current NCEP guidelines),
3(33%) were active smokers. None was under antiischae-
mic therapy (beta-blocker and/or non-dihydropiridinic
calcium antagonist) at the time of SE testing. All of the
patients maintained their usual therapy througout the
study time period, with no exceptions.
All but 2 subjects had normalization of STSD during
repeat SE performed after the 4 month course of therapy.
Of the two subjects still presenting STSD at repeat SE, one
was hypertensive and non-diabetic while the other was
diabetic but non-hypertensive).
Discussion
We tested the study hypothesis in a small series of consec-
utive subjects, with the intent to produce a small hypoth-
esis-generating study; testing the hypothesis in a large,
randomized, placebo-controlled trial was felt premature,
both because we used an innovative, but not definitely
validated marker of coronary endothelial dysfunction and
because lack of strong clinical data about the effect of
PUFAs supplementation on human coronary endothe-
lium.
Our study, as any small "proof of concept" study, has
many limitations:
1) It is a prospective, non-randomized, uncontrolled
interventional study, 2) it is performed in a very small
group of subjects, 3) it is suggestive for a positive-reversal
effect of PUFAs on isolated, angiographically-negative
STSD during SE, but even if recent data strongly suggest
this clinical pattern to be linked with coronary endothelial
dysfunction (5,6), this is not a direct measure of endothe-
lial function and, also, no data exist demonstrating that
reversal of STSD indicates normalization of coronary
endothelial dysfunction.
Of course no subgroup analysis can be performed in such
a small group of subjects, even if it is interesting that non-
responders (2 out of 9 subjects) consisted of one hyper-
tensive, non-diabetic subject and one diabetic non-hyper-
tensive subject, suggesting that inefficacy of therapy may
not be linked to the presence/absence of these clinical
conditions.
Even if evidence is strong for a negative prognostic effect
of coronary endothelial dysfunction on mortality, athero-
sclerosis progression and plaque instability [13], coronary
endothelial function is to date difficult to measure on
clinical grounds: hence it is obvious cardiologists prefer to
dilate what they can clearly see (epicardial stenosis) rather
than pharmacologically engage what they can not meas-
ure (endothelium).
An easy to obtain, clinically useful marker of coronary
endothelial dysfunction such as isolated STSD during SE
in the absence of visible CAD would be very welcome in
the cardiology arena, while the striking effect exerted by
PUFAs in this small study would be even more valuable.
Conclusions
Striking rate of reversion of stress-induced ST-segment
depression after oral n-3 PUFAs suggests reversion of cor-
onary endothelial dysfunction; nonetheless these data
need to be validated in larger, placebo-controlled studies
utilizing direct measurements of coronary endothelial
function.
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